[REVISION HISTORY]
ALS early detection biomarker research – validation
Updated 1 time since CLSTR started tracking revisions of this situation.
What changed
2026-07-30 13:12 UTC → 2026-07-31 02:18 UTC ·
added
removed
ALS early detection biomarker research – validation
In July 2026 a U.S. NIH‑funded team reported in Nature Medicine *Nature Medicine* that a panel of 19 blood proteins can anticipate the clinical onset of amyotrophic lateral sclerosis about 1.6 years ahead. The finding came from 516 plasma samples collected over 18 years from 137 genetically at‑risk participants in the Pre‑fALS cohort and was presented as a potential tool for preventive trial enrollment, though it was not yet a diagnostic test. A follow‑up report later in the month confirmed the panel’s predictive accuracy, showing it outperformed the previously strongest marker (NEFL) and could estimate timing of phenoconversion. Researchers stressed that further validation and adaptation to routine laboratory methods are required before clinical use, but the work underscores highlighting an emerging window for early‑intervention strategies in ALS. Separately, Later in July, scientists at the University of Miami replicated the approach, applying artificial‑intelligence analysis to the same NIH study described a programmable CRISPR‑Cas12a2 enzyme targeting tumor‑specific RNAs, a distinct line Pre‑fALS dataset and reaffirming the 19‑protein panel’s ability to forecast disease onset with an average error of research not expanded about 1.6 years. Independent validation using data from the UK Biobank confirmed the pattern’s broader applicability. The team noted that the assay remains experimental and is being explored as a screening tool to time enrolment in subsequent updates. trials of the experimental drug tofersen, which may delay or prevent onset when given before symptoms appear. The combined reports underscore a converging effort to move from reactive ALS management toward proactive, biomarker‑driven trial design, while emphasizing the need for further validation and clinical‑grade assay development.
Versions
- 2026-07-31 02:18 UTC ALS early detection biomarker research – validation
- 2026-07-30 13:12 UTC ALS early detection biomarker research
Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.